In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
The article provides an in-depth analysis of 12 analyst recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months. Analysts have varied opinions, with most being somewhat bullish. The average 12-month price target is $171.67, a slight decrease from the previous $174.58. Jazz Pharmaceuticals has shown notable revenue growth and strong net margins but faces challenges with return on equity.
October 23, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Jazz Pharmaceuticals has received mixed analyst ratings, with a slight decrease in the average price target to $171.67. The company shows strong revenue growth and net margins but faces challenges with return on equity.
The article highlights mixed analyst ratings for Jazz Pharmaceuticals, with a slight decrease in the average price target. The company's strong revenue growth and net margins are positive, but challenges with return on equity may offset these gains, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100